Takaomi Sanda

Singapore, Singapore

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications

An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression.

An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression.

Journal: Internal medicine (Tokyo, Japan)
Published: January 04, 2026

Refining the simplified frailty scale to improve the risk stratification of patients with multiple myeloma.

Refining the simplified frailty scale to improve the risk stratification of patients with multiple myeloma.

Journal: Journal of geriatric oncology
Published: November 01, 2025

Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.

Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.

Journal: Case reports in oncological medicine
Published: October 21, 2025

Whole Genome and Single-Cell RNA Sequencing Reveals Clonal Evolution and Heterogeneity of Secondary Plasma Cell Leukemia: A Case Report.

Whole Genome and Single-Cell RNA Sequencing Reveals Clonal Evolution and Heterogeneity of Secondary Plasma Cell Leukemia: A Case Report.

Journal: EJHaem
Published: August 29, 2025

Non-canonical role of RCoR2: The repressor turns activator.

Non-canonical role of RCoR2: The repressor turns activator.

Journal: Cell reports
Published: June 11, 2025

Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma.

Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma.

Journal: Cancer science
Published: March 19, 2025

Prevalence of CCR7-Positive CD8 T Cells as a Prognostic Factor in B-Cell Maturation Antigen -Targeted Chimeric Antigen Receptor T Cell Therapy.

Prevalence of CCR7-Positive CD8 T Cells as a Prognostic Factor in B-Cell Maturation Antigen -Targeted Chimeric Antigen Receptor T Cell Therapy.

Journal: EJHaem
Published: February 20, 2025

Neuroblastoma cell growth and survival promoted by DNMT3B and its inhibition demonstrates anti-tumor effects.

Neuroblastoma cell growth and survival promoted by DNMT3B and its inhibition demonstrates anti-tumor effects.

Journal: Pediatric research
Published: January 15, 2025

Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.

Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.

Journal: British journal of haematology
Published: January 07, 2025

Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.

Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.

Journal: Leukemia
Published: June 18, 2024

T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation.

T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation.

Journal: Cancer cell
Published: June 11, 2024

Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.

Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.

Journal: Cell reports. Medicine
Published: May 27, 2024
Showing 1-12 of 85

Last Updated: 09/26/2026